People getting vaccinated may still have questions about COVID-19 vaccines, like why it takes two doses — and then two weeks — to take full effect.
THE CANADIAN PRESS/Ryan Remiorz
A medical student answers questions he gets asked at a COVID-19 vaccine clinic: Efficacy versus real-world effectiveness, immune response and how the mRNA vaccines compare to vaccines already in wide use.
FDA approval of Pfizer’s COVID-19 vaccine may boost vaccination rates among those who have been hesitant to get the shot.
(AP Photo/Jessica Hill)
The U.S. FDA has approved the first COVID-19 vaccine. How is approval different from emergency use authorization, and what difference will it make to a vaccine that’s already in global use?
Potential benefits of human genome editing include new ways to diagnose, treat and prevent genetic disorders. But there’s a significant gap in regulation.
Full FDA approval of the COVID-19 vaccines may help people feel more secure in its safety and effectiveness.
SOPA Images/LightRocket via Getty Images
While emergency use authorization gets vaccines out to the public more quickly, it doesn’t skip any steps that full approval requires.
Vaccine efficacy statistics are often based on the results of randomized controlled trials.
Vaccine efficacy is usually expressed as a percentage, but what is it actually measuring? Statisticians explain what the numbers mean, and what they say about how well a vaccine can protect us.
Crystal jellyfish contain glowing proteins that scientists repurpose for an endless array of studies.
Weili Li/Moment via Getty Images
Three pioneering technologies have forever altered how researchers do their work and promise to revolutionize medicine, from correcting genetic disorders to treating degenerative brain diseases.
What kind of vaccine is Sputnik V, how does it work, and what data are we missing?
Investigations have led to the withdrawal of a study backing ivermectin to treat COVID-19. But that’s not the last time we’ll hear about this controversial drug.
Information on COVID-19 vaccines for pregnant or breastfeeding individuals has been inconsistent and hard to find.
(AP Photo/Charles Krupa)
Exclusion from clinical trials, lack of data and inconsistent information made it difficult for pregnant and breastfeeding people to make decisions about COVID-19 vaccines early in the rollout.
Put into context, the benefits of vaccination still far outweigh the risks of rare adverse events.
PenWin/iStock via Getty Images Plus
Ongoing tracking is meant to spot very rare risks – like the connection between the Johnson & Johnson shot and Guillain-Barré syndrome. And it relies on public reporting.
The freedom of going mask-free is still a ways off for kids under age 12.
Juan Monino/E+ via Getty Images
As many teens and adults in the US restart their social lives, parents of children under the age of 12 wonder when their kids will also be able to experience the freedom that comes with vaccination.
Relying on donor funding means that the funder ultimately determines the health priorities. This is one reason why many programmes in Africa focus on a single disease such as HIV.
A new network of public clinical trials institutes is urgently needed to replenish the empty pipeline for new antibiotics.
While it’s potentially promising, there’s not enough information yet to determine if the vaccine is safe and effective.
Even if we came up with a definition of what makes the “best” vaccine, we don’t have the luxury of choice, when vaccines are in short supply.
Alzheimer’s disease is characterized by progressive memory loss, spatial disorientation and many other cognitive and behavioural disorders that ultimately lead to a state of total dependence.
The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
Do the benefits of approving a drug before confirming it works outweigh the potential costs?
monkeybusinessimages/iStock via Getty Images Plus
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
It sounds too good to be true, a vaccine that can protect against future virus variants. But governments around the world are keen to learn more.
A COVID-19 vaccine is administered at a clinic at Olympic Stadium in Montréal on March 1, 2021, marking the beginning of mass vaccination in the Province of Québec based on age.
THE CANADIAN PRESS/Paul Chiasson
With four COVID-19 vaccines approved for use in Canada, it’s time to answer FAQs about efficacy, immunity, eradication and variants.
By - https://www.nlm.nih.gov/hmd/emotions/self.html , , Public Domain, https://commons.wikimedia.org/w/index.php?curid=1684469.
Elaine and Arthur Shapiro/Wikimedia Commons
A whistle-stop tour of the history of placebos.